- Home
- BCDA vs BMRA Comparison
BCDA vs BMRA Comparison
Compare BCDA & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- BMRA
- Stock Information
- Founded
- BCDA N/A
- BMRA 1971
- Country
- BCDA United States
- BMRA United States
- Employees
- BCDA N/A
- BMRA N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCDA Health Care
- BMRA Health Care
- Exchange
- BCDA Nasdaq
- BMRA Nasdaq
- Market Cap
- BCDA 9.4M
- BMRA 9.2M
- IPO Year
- BCDA N/A
- BMRA N/A
- Fundamental
- Price
- BCDA $2.32
- BMRA $3.67
- Analyst Decision
- BCDA Strong Buy
- BMRA
- Analyst Count
- BCDA 1
- BMRA 0
- Target Price
- BCDA $25.00
- BMRA N/A
- AVG Volume (30 Days)
- BCDA 102.2K
- BMRA 48.3K
- Earning Date
- BCDA 05-14-2025
- BMRA 04-14-2025
- Dividend Yield
- BCDA N/A
- BMRA N/A
- EPS Growth
- BCDA N/A
- BMRA N/A
- EPS
- BCDA N/A
- BMRA N/A
- Revenue
- BCDA $58,000.00
- BMRA $5,678,000.00
- Revenue This Year
- BCDA N/A
- BMRA N/A
- Revenue Next Year
- BCDA N/A
- BMRA N/A
- P/E Ratio
- BCDA N/A
- BMRA N/A
- Revenue Growth
- BCDA N/A
- BMRA 5.01
- 52 Week Low
- BCDA $1.63
- BMRA $1.92
- 52 Week High
- BCDA $6.15
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- BCDA 45.74
- BMRA 46.61
- Support Level
- BCDA $2.40
- BMRA $3.41
- Resistance Level
- BCDA $2.92
- BMRA $3.74
- Average True Range (ATR)
- BCDA 0.31
- BMRA 0.30
- MACD
- BCDA -0.00
- BMRA 0.05
- Stochastic Oscillator
- BCDA 9.28
- BMRA 43.29
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.